In 2023, Stéphane Bancel earned $4.56M in total compensation at Moderna, including $1.58M salary and $1.91M bonus. Most recently acquired 26,466 shares in Feb 2025. Currently holds stock worth $373.28M. Has donated $14.06M in stock to charitable causes. Has led Moderna for over 12 years.
Compensation History
Annual executive compensation data for Stéphane Bancel, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$4.56M
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Salary
$1.58MBoard Justification
The compensation philosophy is focused on performance-based incentives to align with company performance and shareholder interests.
Bonus
$1.91MBoard Justification
Based on target of 150% of salary, with 81% payout, reflecting 90% individual assessment.
Other Compensation
$1.07MBoard Justification
Includes 401(k) match, security services, and other benefits.
Restricted Stock
Board Justification
No stock grants vested in 2023.
Performance Metrics
Performance metrics include product sales from COVID-19 vaccines, operating income, and total shareholder return.
Stéphane Bancel
CEO of Moderna
Education
MBA from Harvard Business School; Master's in Management from the Ecole Centrale Paris.
Field of Expertise
Healthcare & Life Sciences - Biotechnology
Sector of Economy
Healthcare
Born
April 20, 1972 - 53 years ago
CEO of Moderna for
12 years 2 months (Oct 2013 - Present)
Previous Experience
CEO of Moderna, Inc. since 2013; previously held various roles at BioMérieux and Eli Lilly.
Holdings
Track Stéphane Bancel's stock holdings and portfolio value over time.
Total Stock Sold
$1.20B
$1.20B
8,129,809 MRNA shares
What if they kept their stock?
If Stéphane Bancel didn't sell their stock, today they would have:
Extra MRNA8,129,809 shares worth $207.19M.
This is -82.66% and $987.98M less than what they got when they sold the stock.
Charitable Transactions
551,755 shares
MRNA
Recent Charitable Transactions
4,000 shares
MRNA
May 18, 2022
Charity
4,000 shares
MRNA
May 11, 2022
Charity
4,000 shares
MRNA
May 4, 2022
Charity
4,000 shares
MRNA
Apr 27, 2022
Charity
4,000 shares
MRNA
Apr 20, 2022
Charity
4,000 shares
MRNA
Apr 13, 2022
Charity
Insider Trading
Stéphane Bancel's recent stock transactions, purchases, and sales filed with the SEC.
26,466 shares
MRNA
Feb 12, 2025
Received
$2.34M
MRNA at $88.88/share
Feb 14, 2024
Sale
56,736 shares
MRNA
Feb 14, 2024
Received
$3.31M
MRNA at $121.71/share
Jun 28, 2023
Sale
$9.66M
MRNA at $120.74/share
Jun 21, 2023
Sale
$10.18M
MRNA at $127.27/share
Jun 14, 2023
Sale
$10.01M
MRNA at $125.11/share
Jun 7, 2023
Sale
$10.17M
MRNA at $127.15/share
May 31, 2023
Sale
$10.37M
MRNA at $129.59/share
May 24, 2023
Sale
$9.99M
MRNA at $124.86/share
May 17, 2023
Sale
Rivals
Compare Stéphane Bancel with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Vladimir Tenev
Founder and CEO of Robinhood Markets, Inc.
2024 Compensation
Stock
$2.75M
Salary
$34.25K
Bonus
$0.00
Other
$2.10M
Total Holdings
$25.08M
Stanley C. Erck
CEO of Novavax
2023 Compensation
Stock
$129.78K
Salary
$50.90K
Bonus
$0.00
Other
$3.83M
Total Holdings
$4.60M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Elon Musk
Founder and CEO of Tesla, Inc.
2024 Compensation
Stock
$0.00
Salary
$0.00
Bonus
$0.00
Other
$0.00
Total Holdings
$171.47B